SSA
LVTX

Schonfeld Strategic Advisors’s LAVA Therapeutics LVTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,300
Closed -$60.9K – 2393
2024
Q1 		$60.9K Buy
+18,300
New +$40.3K ﹤0.01% 1891

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Schonfeld Strategic Advisors's LVTX Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of LAVA Therapeutics (LVTX) in Q2 2024, closing a stake of 18,300 shares — an estimated $60.9K sold.

Schonfeld Strategic Advisors first reported a position in LVTX in Q1 2024 and held it in 1 quarter. The position peaked at $60.9K in Q1 2024. 19 funds tracked by Wall St. Rank hold LVTX as of Q2 2024.

  • Schonfeld Strategic Advisors reported no remaining LAVA Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 18,300 LAVA Therapeutics shares in Q2 2024, an estimated $60.9K.
  • Schonfeld Strategic Advisors first reported a position in LAVA Therapeutics in Q1 2024 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's LAVA Therapeutics position peaked at $60.9K in Q1 2024.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.